cover of episode WeightWatchers CEO Sima Sistani talks TikTok, Telehealth Deal on GLP-1/Ozempic and Why She Took the Job

WeightWatchers CEO Sima Sistani talks TikTok, Telehealth Deal on GLP-1/Ozempic and Why She Took the Job

2023/4/6
logo of podcast On with Kara Swisher

On with Kara Swisher
AI Deep Dive AI Chapters Transcript
People
K
Kara Swisher
卡拉·斯威舍是一位知名的媒体评论家和播客主持人，专注于科技和政治话题的深入分析。
N
Naeem Araza
S
Seema Sistani
Topics
Kara Swisher和Naeem Araza：讨论Weight Watchers收购Sequence公司，进军处方药领域，引发了关于个人责任与医疗干预的讨论。他们认为，虽然Ozempic等药物对部分肥胖人士有效，但不能完全解决问题，还应关注食品供应、企业贪婪和监管不足等根本原因。他们还讨论了社会对使用减肥药物的偏见，以及人们对快速减肥的渴望。 Seema Sistani：阐述了Weight Watchers的转型战略，从注重个人责任转向整合医疗干预。她解释了收购Sequence公司的目的，以及如何通过结合行为改变和临床干预来帮助用户更好地管理体重。她强调，并非所有用户都需要药物治疗，只有在医学上适宜的情况下才会推荐。她还谈到了公司在数字化转型方面的努力，以及如何利用技术改进用户体验，并打击市场上的不良行为。她认为，社会对肥胖的污名化导致人们对GLP-1类药物的关注点偏离了其真正的价值，即预防慢性疾病。她还呼吁改变人们对饮食的负面看法，推广健康的生活方式，并避免用户出现饮食失调等问题。最后，她强调Weight Watchers是一家以软件为核心的科技公司，致力于帮助人们拥有更健康的生活方式，并延长寿命。

Deep Dive

Chapters
Weight Watchers announces a $132 million deal to acquire Sequence, a telehealth company that prescribes GLP-1 drugs, raising questions about the company's shift from personal accountability to medical intervention.

Shownotes Transcript

WeightWatchers recently announced a $132 million deal to acquire telehealth company Sequence and enter the prescription drug space (think: GLP-1 drugs like Wegovy and Ozempic). It begs the question: why is a company built on personal accountability facilitating medical interventions? We ask our guest, WeightWatchers CEO Sima Sistani. Before and after the interview, Nayeema and Kara discuss their own experiences with diet fads and whether drugs like Wegovy and Ozempic will help America deal with the obesity epidemic or simply avoid tackling underlying issues like food supply, corporate greed and light regulation.

Questions? Comments? Email us at [email protected] or find us on Twitter @karaswisher and @nayeema 

Learn more about your ad choices. Visit podcastchoices.com/adchoices)